ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2022 American Transplant Congress

    The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients

    K. Nunez, T. Sandow, P. Thevenot, A. Cohen

    Ochsner Health System, New Orleans, LA

    *Purpose: Response to locoregional therapy (LRT) in hepatocellular carcinoma (HCC) impacts both progression-free survival (PFS) and bridge to transplant success. Yttrium-90 (Y90) is an effective…
  • 2022 American Transplant Congress

    Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, Y. Imaoka2, K. Sato3, K. Imaoka1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. G. Tzakis4, S. Nishida5, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2Hiroshima Uni., Hiroshima, Japan, 3Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, 4Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, 5Univ of Miami School of Medicine, Valhalla, NY

    *Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
  • 2022 American Transplant Congress

    Impact of MMaT Policy on Transplant for Hepatocellular Carcinoma at a Single Center

    S. Kodali1, D. W. Victor2, J. Corkrean2, A. Shetty2, C. Mobley2, M. Hobeika2, R. McMillan2, E. A. Graviss3, D. T. Nguyen3, R. McFadden4, V. Ankoma-Sey2, C. Egwim5, J. Galati2, A. Saharia2, R. M. Ghobrial2

    1Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Sugarland, TX, 2Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, 3Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, 4Department of Medicine, Hepatology, Houston Methodist Hospital, Houston, TX, 5Houston Methodist Hospital, Houston, TX

    *Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor. Currently, liver transplantation may be the optimal treatment for HCC. Patient selection criteria…
  • 2022 American Transplant Congress

    Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality

    C. Durkin1, T. Bittermann1, D. E. Schaubel2

    1Gastroenterology, University of Pennsylvania, Philadelphia, PA, 2Biostatistics, University of Pennsylvania, Philadelphia, PA

    *Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
  • 2022 American Transplant Congress

    A Intention-to-Treat Analysis of 881 Consecutively Waitlisted Patients to Develop a Survival Benefit Model for Hepatocellular Carcinoma Liver Transplant Candidates

    B. V. Tran1, W. Lapisatepun1, W. Dumronggittigule1, D. Markovic2, Y. Lee1, F. Kaldas1, D. Farmer1, R. Busuttil1, V. Agopian1

    1Department of Surgery, University of California Los Angeles, Los Angeles, CA, 2Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA

    *Purpose: The current liver transplantation (LT) selection paradigm for hepatocellular carcinoma (HCC) patients ignores the variable risks of waitlist dropout and post-LT recurrence/death, with the…
  • 2022 American Transplant Congress

    Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation

    G. Orozco1, R. Gedaly2, L. Turcios2, F. Marti2

    1Surgery, University of Kentucky, Lexington, KY, 2UKHC, Lexington, KY

    *Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…
  • 2022 American Transplant Congress

    Immune Checkpoints, Immune Cells, and MHC Expression in the Tumor Microenvironment of Resected Hepatocellular Carcinomas

    A. Baquerizo1, V. Vavinskaya2, S. Bagsic1, A. Rojas3, A. Mhoyan4, C. Frenette1, L. Sher5, M. Romero3, J. Fisher1, C. Marsch1, R. Schaffer1

    1Scripps, La Jolla, CA, 2UCSD, San Diego, CA, 3University, Seville, Spain, 4Kaiser, San Diego, CA, 5USC, Los Angeles, CA

    *Purpose: Advances in tumor biology has shown the important role of the tumor microenvironment (TME) in tumor growth and metastasis. A better understanding of the…
  • 2022 American Transplant Congress

    Disparities in Liver Transplantation in Patients with HCC Diagnosis

    C. Warren1, A. Zarrinpar2

    1Surgery, University of Florida Shands Health, Gainesville, FL, 2Surgery, University of Florida Health Shands, Gainesville, FL

    *Purpose: Disparities in outcomes of hepatocellular carcinoma (HCC) have not been adequately studied, especially in the context of liver transplantation (LT). We sought to identify…
  • 2022 American Transplant Congress

    Liver Transplantation for Patients with Fibrolamellar Hepatocellular Carcinoma: A Comprehensive Multicenter Analysis to Support Future Decision Making

    M. P. Claasen1, T. Ivanics1, W. G. Polak2, J. N. IJzermans2, G. Sapisochin1

    1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands

    *Purpose: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare tumour accounting for ~1% of all primary liver cancers. Due to its rarity, there is a shortage…
  • 2022 American Transplant Congress

    Differentially Methylated Genes Predict Post-Transplant Relapse of Unresectable Hepatoblastoma

    M. Ningappa1, M. Muarya2, C. Ashokkumar1, H. Hakonarson3, S. Subramaniam4, R. Sindhi1

    1Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Department of Bioengineering & San Diego Supercomputer Center, University of California, San Diego, CA, 3Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 4Department of Computer Science and Engineering, and Nanoengineering, University of California, San Diego, La Jolla, CA

    *Purpose: Hepatoblastoma (HB), a developmental liver tumor of childhood requires liver transplantation (LT) if it remains unresectable despite chemotherapy. Post-transplant relapse in up to 20%…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences